742-P: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes

Introduction 5.7%, and 43.7% had body weight reductions ≥5% from baseline. Ecnoglutide was safe and well tolerated. The proportion of participants reporting any adverse event (AE) ranged from 77.5 to 78.3% for ecnoglutide groups and 60.6% for placebo. Four (2.9%) treatment-related ≥Grade 3 AEs and one (0.7%) treatment-related serious AE occurred in the ecnoglutide groups. One participant from each cohort discontinued due to an AE. The most frequently reported AEs were decreased appetite, diarrhea, and nausea, which were mostly mild to moderate and transient. Conclusion: Ecnoglutide resulted in robust HbA1c declines of up to 2.43% from baseline after 24 weeks of treatment in adults with T2DM, with up to 35.2% of participants reaching normoglycemia (HbA1c 5.7%) and 43.7% with weight reductions ≥5%. Disclosure D. Zhu: None. W. Wang: None. G. Tong: None. J. Ma: None. B. Wen: None. X. Zheng: None. B. Shi: None. S. Pang: None. S. Bing: Employee; Sciwind Biosciences, Keymed Biosciences. Q. Zheng: Employee; Sciwind Biosciences. G. Lei: None. F. Jiang: Employee; Sciwind Biosciences, PrimeGene Biosciences. X. Liu: None. Y. Bu: None. J. Ning: None. Z. Zhu: None. L. Yang: Employee; Sciwind Biosciences. M. Yang: Employee; Sciwind Biosciences. M. Fenaux: None. M.K. Junaidi: None. S. Xu: None. Funding Sciwind Biosciences